| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for MEDANTA from our risk checks.
Global Health Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,356.20 |
| 52 Week High | ₹1,513.90 |
| 52 Week Low | ₹629.00 |
| Beta | 0 |
| 1 Month Change | -3.19% |
| 3 Month Change | 20.99% |
| 1 Year Change | 109.10% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 226.56% |
Recent News & Updates
Global Health Limited's (NSE:MEDANTA) Share Price Matching Investor Opinion
May 22
Global Health Limited (NSE:MEDANTA) Yearly Results Just Came Out: Here's What Analysts Are Forecasting For This Year
May 22Returns On Capital Are Showing Encouraging Signs At Global Health (NSE:MEDANTA)
May 04Recent updates
Global Health Limited's (NSE:MEDANTA) Share Price Matching Investor Opinion
May 22Global Health Limited (NSE:MEDANTA) Yearly Results Just Came Out: Here's What Analysts Are Forecasting For This Year
May 22Returns On Capital Are Showing Encouraging Signs At Global Health (NSE:MEDANTA)
May 04Do Global Health's (NSE:MEDANTA) Earnings Warrant Your Attention?
Apr 12Is Global Health (NSE:MEDANTA) A Risky Investment?
Mar 22Market Participants Recognise Global Health Limited's (NSE:MEDANTA) Earnings Pushing Shares 32% Higher
Feb 13There's Been No Shortage Of Growth Recently For Global Health's (NSE:MEDANTA) Returns On Capital
Jan 18With EPS Growth And More, Global Health (NSE:MEDANTA) Makes An Interesting Case
Dec 26Global Health Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Jun 01Global Health Limited's (NSE:MEDANTA) Earnings Haven't Escaped The Attention Of Investors
Mar 30Shareholder Returns
| MEDANTA | IN Healthcare | IN Market | |
|---|---|---|---|
| 7D | 10.5% | 5.3% | 2.7% |
| 1Y | 109.1% | 42.7% | 44.9% |
Return vs Industry: MEDANTA exceeded the Indian Healthcare industry which returned 40.6% over the past year.
Return vs Market: MEDANTA exceeded the Indian Market which returned 44.7% over the past year.
Price Volatility
| MEDANTA volatility | |
|---|---|
| MEDANTA Average Weekly Movement | 6.0% |
| Healthcare Industry Average Movement | 6.0% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in IN Market | 9.4% |
| 10% least volatile stocks in IN Market | 4.3% |
Stable Share Price: MEDANTA has not had significant price volatility in the past 3 months.
Volatility Over Time: MEDANTA's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 7,829 | Pankaj Sahni | www.medanta.org |
Global Health Limited engages in the provision of healthcare services in India. The company primarily offers treatments in the areas of lung transplant, mother and child care, neonatology, URO-oncology, paediatric, pulmonology, oncology, orthopaedics, urology, endocrine surgery, gastroenterology, Psychiatry, surgical and radiation oncology, as well as ENT, blood bank, and chest related services. It also offers digestive and hepatobiliary sciences, musculoskeletal disorders and orthopedics, critical care and anesthesiology, endocrinology and diabetology, nephrology, obstetrics, dermatology, ophthalmology, dental, liver transplant, kidney, and various specializations, as well as ayurvedic medicine.
Global Health Limited Fundamentals Summary
| MEDANTA fundamental statistics | |
|---|---|
| Market cap | ₹364.15b |
| Earnings (TTM) | ₹4.78b |
| Revenue (TTM) | ₹32.75b |
76.2x
P/E Ratio11.1x
P/S RatioIs MEDANTA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MEDANTA income statement (TTM) | |
|---|---|
| Revenue | ₹32.75b |
| Cost of Revenue | ₹14.94b |
| Gross Profit | ₹17.81b |
| Other Expenses | ₹13.03b |
| Earnings | ₹4.78b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 17.81 |
| Gross Margin | 54.38% |
| Net Profit Margin | 14.60% |
| Debt/Equity Ratio | 14.4% |
How did MEDANTA perform over the long term?
See historical performance and comparison